Shattuck Labs (STTK) Liabilities and Shareholders Equity (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Liabilities and Shareholders Equity of $102.1 million for Q1 2026, up 32.34% year-over-year from $77.2 million in Q1 2025, and up 12.19% quarter-over-quarter from $91.0 million in Q4 2025.
Shattuck Labs (STTK) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $102.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 32.34% year-over-year to $102.1 million; the TTM figure through Mar 2026 stood at $357.9 million (down 12.41% YoY), while the FY2025 annual figure was $91.0 million, changed 0.03% from the prior year.
- Liabilities and Shareholders Equity climbed to $102.1 million in Q1 2026 per STTK's latest filing, from $91.0 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $270.5 million in Q1 2022 and bottomed at $64.4 million in Q2 2025.
- Historically, Liabilities and Shareholders Equity has averaged $146.2 million across 5 years, with a median of $130.5 million in 2023.
- Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity tumbled 49.95% — and 2026, when it surged 32.34%.
- Shattuck Labs' Liabilities and Shareholders Equity stood at $205.3 million in 2022, then retreated by 22.29% to $159.6 million in 2023, then sank by 42.94% to $91.0 million in 2024, then retreated by 0.03% to $91.0 million in 2025, then climbed by 12.19% to $102.1 million in 2026.
- Business Quant data shows STTK's Liabilities and Shareholders Equity at $102.1 million in Q1 2026, $91.0 million in Q4 2025, and $100.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - | 220.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 220.67 Mn |
| Mar 31, 2026 | 102.12 Mn |
| Dec 31, 2025 | 91.03 Mn |
| Sep 30, 2025 | 100.33 Mn |
| Jun 30, 2025 | 64.37 Mn |
| Mar 31, 2025 | 77.17 Mn |
| Dec 31, 2024 | 91.05 Mn |
| Sep 30, 2024 | 111.72 Mn |
| Jun 30, 2024 | 128.61 Mn |
| Mar 31, 2024 | 146.34 Mn |
| Dec 31, 2023 | 159.56 Mn |
| Sep 30, 2023 | 130.46 Mn |
| Jun 30, 2023 | 155.27 Mn |
| Mar 31, 2023 | 177.68 Mn |
| Dec 31, 2022 | 205.32 Mn |
| Sep 30, 2022 | 222.94 Mn |
| Jun 30, 2022 | 251.34 Mn |
| Mar 31, 2022 | 270.49 Mn |
| Dec 31, 2021 | 298.59 Mn |
| Sep 30, 2021 | 310.57 Mn |